Neuren Pharmaceuticals Ltd
ASX:NEU
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.25
25.11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Neuren Pharmaceuticals Ltd
Net Margin
Neuren Pharmaceuticals Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | AU |
| Market Cap | 1.6B AUD |
| Net Margin |
57%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Net Margin |
-79%
|
| Country | US |
| Market Cap | 758.5B USD |
| Net Margin |
20%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Net Margin |
-4%
|
| Country | DK |
| Market Cap | 3.4T DKK |
| Net Margin |
35%
|
| Country | US |
| Market Cap | 372B USD |
| Net Margin |
17%
|
| Country | US |
| Market Cap | 253B USD |
| Net Margin |
19%
|
| Country | CH |
| Market Cap | 200.4B CHF |
| Net Margin |
20%
|
| Country | UK |
| Market Cap | 162.7B GBP |
| Net Margin |
13%
|
| Country | CH |
| Market Cap | 179.9B CHF |
| Net Margin |
35%
|
| Country | IE |
| Market Cap | 146B USD |
| Net Margin |
-126%
|
Neuren Pharmaceuticals Ltd
Glance View
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The firm has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. The company is also planning a Phase II trial in Prader-Willi syndrome.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Neuren Pharmaceuticals Ltd's most recent financial statements, the company has Net Margin of 57.4%.
You don't have any saved screeners yet
